A Phase 2/3 interventional study of toremifene or tamoxifen in Breast Cancer Patients in Premenopausal and Estrogen and/or Progesterone Receptor Positive, sponsored by Fengxi Su. Status unknown at 1 site in China. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-05-06.
Sponsored by Fengxi Su · Phase 2/3, Interventional, and Treatment
In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 3,036 is above the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Fengxi Su is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
tamoxifen,20mg/day
Drug: toremifene or tamoxifen
toremifene,60mg/day
Drug: toremifene or tamoxifen
survival outcomes: disease free survival
Time frame: up to 5 years
5-year overall survival
Time frame: up to 5 years
side effects effects of therapies
the primary safety measures are Hepatic function and blood lipid
Time frame: Follow-up period,up to 5 years
Incidence of adverse events
Adverse events including hot flashes, irregular menses and others.
Time frame: follow-up period, up to 5 years
This study is status unknown, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fengxi Su